Could DIZE be the answer to COVID-19?
作者信息
Qaradakhi Tawar, Gadanec Laura, Matsoukas John, Apostolopoulos Vasso, Zulli Anthony
机构信息
Institute for Health and Sport, Victoria University, Melbourne, VIC, Australia.
NewDrug S.A., Patras Science Park, Patras, Greece.
出版信息
Maturitas. 2020 Oct;140:83-84. doi: 10.1016/j.maturitas.2020.07.002. Epub 2020 Jul 2.
Abstract
摘要
相似文献
1
Could DIZE be the answer to COVID-19?二氢杨梅素（DIZE）会是新冠病毒病（COVID-19）的解决方案吗？
Maturitas. 2020 Oct;140:83-84. doi: 10.1016/j.maturitas.2020.07.002. Epub 2020 Jul 2.
2
Nasal ACE2 Levels and COVID-19 in Children.儿童鼻腔血管紧张素转换酶2水平与新型冠状病毒肺炎
JAMA. 2020 Jun 16;323(23):2386-2387. doi: 10.1001/jama.2020.8946.
3
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.对近期有关血管紧张素转换酶2（ACE2）和肾素-血管紧张素系统阻滞剂与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关性的评论的回应
Drug Dev Res. 2020 Sep;81(6):643-646. doi: 10.1002/ddr.21672. Epub 2020 Apr 17.
4
Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research.新型冠状病毒肺炎与血管紧张素转换酶2（ACE2）：研究领域
Heart Lung. 2020 Jul-Aug;49(4):351. doi: 10.1016/j.hrtlng.2020.04.012. Epub 2020 Apr 20.
5
ACE2 is on the X chromosome: could this explain COVID-19 gender differences?血管紧张素转换酶2位于X染色体上：这能解释新冠病毒病的性别差异吗？
Eur Heart J. 2020 Jun 1;41(32):3095. doi: 10.1093/eurheartj/ehaa521.
6
What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?血管紧张素转换酶2（ACE2）在合并糖尿病的高血压患者感染新型冠状病毒肺炎（COVID-19）中起什么作用？
Can J Cardiol. 2020 Jun;36(6):969.e3. doi: 10.1016/j.cjca.2020.03.049. Epub 2020 Apr 8.
7
Mechanisms by which angiotensin-receptor blockers increase ACE2 levels.血管紧张素受体阻滞剂增加ACE2水平的机制。
Nat Rev Cardiol. 2020 Jun;17(6):378. doi: 10.1038/s41569-020-0387-7.
8
New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.心房颤动患者可溶性血管紧张素转换酶2的新数据揭示了其在治疗新冠病毒肺炎和心血管疾病患者中的潜在价值。
Eur Heart J. 2020 Nov 1;41(41):4047-4049. doi: 10.1093/eurheartj/ehaa761.
9
Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link.血管紧张素转换酶2、性别差异与2019冠状病毒病：缺失的环节
Int J Cardiol. 2021 Jan 1;322:293. doi: 10.1016/j.ijcard.2020.09.018. Epub 2020 Sep 10.
10
Blockade of SARS-CoV-2 infection by recombinant soluble ACE2.重组可溶性血管紧张素转换酶2对严重急性呼吸综合征冠状病毒2感染的阻断作用
Kidney Int. 2020 Jun;97(6):1091-1093. doi: 10.1016/j.kint.2020.04.009. Epub 2020 Apr 14.
引用本文的文献
1
Decoy peptides effectively inhibit the binding of SARS-CoV-2 to ACE2 on oral epithelial cells.诱饵肽可有效抑制新型冠状病毒与口腔上皮细胞上血管紧张素转换酶2的结合。
Heliyon. 2023 Nov 20;9(12):e22614. doi: 10.1016/j.heliyon.2023.e22614. eCollection 2023 Dec.
2
Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.血管紧张素 II 在心血管疾病中的作用：双沙坦作为 2019 年冠状病毒新型治疗方法的介绍。
Biomolecules. 2023 May 2;13(5):787. doi: 10.3390/biom13050787.
3
Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity.SARS-CoV-2 的分子流行病学：精氨酸在突变和传染性方面的主导作用。
Viruses. 2023 Jan 22;15(2):309. doi: 10.3390/v15020309.
4
An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.血管紧张素转换酶2的结构/功能、多态性及其在2019冠状病毒病病理生理学中的双重性质的最新进展：对与严重急性呼吸综合征冠状病毒感染相关的血管和凝血疾病的影响。
Front Microbiol. 2022 Nov 28;13:1042200. doi: 10.3389/fmicb.2022.1042200. eCollection 2022.
5
Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.乙酰氨基阿维菌素可减轻血管紧张素 II 收缩作用并与严重急性呼吸综合征冠状病毒 2 的刺突蛋白相互作用。
Biomedicines. 2022 Jul 18;10(7):1731. doi: 10.3390/biomedicines10071731.
6
Diminazene Aceturate Stabilizes Atherosclerotic Plaque and Attenuates Hepatic Steatosis in apoE-Knockout Mice by Influencing Macrophages Polarization and Taurine Biosynthesis.二甲硝咪唑乙酰丙酮通过影响巨噬细胞极化和牛磺酸生物合成稳定动脉粥样硬化斑块并减轻载脂蛋白 E 基因敲除小鼠的肝脂肪变性。
Int J Mol Sci. 2021 May 30;22(11):5861. doi: 10.3390/ijms22115861.
7
Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.Toll样受体4和血管紧张素转换酶2的双重靶向：一种治疗新型冠状病毒肺炎的建议方法。
Future Microbiol. 2021 Mar;16:205-209. doi: 10.2217/fmb-2021-0018. Epub 2021 Feb 11.
8
From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.从血管紧张素 II 到环肽和血管紧张素受体阻滞剂 (ARB)：ARB 在 COVID-19 治疗中的观点。
Molecules. 2021 Jan 25;26(3):618. doi: 10.3390/molecules26030618.
9
A Global Review on Short Peptides: Frontiers and Perspectives.短肽的全球研究综述：前沿与展望。
Molecules. 2021 Jan 15;26(2):430. doi: 10.3390/molecules26020430.
本文引用的文献
1
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.血管紧张素转换酶 2 与抗高血压药物（血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂）在 2019 冠状病毒病中的作用。
Mayo Clin Proc. 2020 Jun;95(6):1222-1230. doi: 10.1016/j.mayocp.2020.03.026. Epub 2020 Apr 4.
2
CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19).CD-sACE2 包含物：一种针对 2019 年冠状病毒病（COVID-19）的有效治疗方法。
J Med Virol. 2020 Oct;92(10):1721-1723. doi: 10.1002/jmv.25804. Epub 2020 Apr 17.
3
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.强效泛冠状病毒融合抑制剂抑制 SARS-CoV-2（前称 2019-nCoV）感染，该抑制剂针对病毒的刺突蛋白，具有很强的介导膜融合能力。
Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.
4
Antihypertensive drugs and risk of COVID-19? - Authors' reply.抗高血压药物与2019冠状病毒病风险？——作者回复
Lancet Respir Med. 2020 May;8(5):e32-e33. doi: 10.1016/S2213-2600(20)30159-4. Epub 2020 Mar 26.
5
Antihypertensive drugs and risk of COVID-19?抗高血压药物与新冠病毒病风险？
Lancet Respir Med. 2020 May;8(5):e30-e31. doi: 10.1016/S2213-2600(20)30153-3. Epub 2020 Mar 26.
6
Facts and reflections on COVID-19 and anti-hypertensives drugs.关于新冠病毒肺炎与抗高血压药物的事实与思考。
Drug Discov Ther. 2020 May 6;14(2):105-106. doi: 10.5582/ddt.2020.01017. Epub 2020 Mar 26.
7
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
8
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
9
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.血管紧张素受体阻滞剂可作为治疗 SARS-CoV-2 的候选药物。
Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
10
Structure analysis of the receptor binding of 2019-nCoV.2019新型冠状病毒受体结合的结构分析
Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40. doi: 10.1016/j.bbrc.2020.02.071.
Zotero 插件